Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates
11 nov. 2021 16h00 HE
|
Vyant Bio, Inc.
Strategic Highlights Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bio’s R&D programs targeting the identification of novel therapeuticsEntered into two new first...
Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference
10 nov. 2021 16h15 HE
|
Vyant Bio, Inc.
Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Vyant Bio Announces Investor Conference Call and Webcast for the Third Quarter 2021
09 nov. 2021 09h15 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Vyant Bio Announces Robert T. Fremeau, Jr. Ph.D. as Chief Scientific Officer
26 oct. 2021 08h00 HE
|
Vyant Bio, Inc.
Cherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company identifying small and large molecule...
マソリ･セラピューティックスとビヤント･バイオ、新たな提携を発表
19 oct. 2021 16h47 HE
|
Vyant Bio, Inc.
メリーランド州ベセスダ、東京、ニュージャージー州チェリーヒル発, Oct. 20, 2021 (GLOBE NEWSWIRE) -- 革新的な市場ソリューションの創出を通じて、競争上の優位性を達成するために人工知能を適用する、製薬業界に特化した企業であるマソリ･セラピューティックス (MASORI Therapeutics) と、中枢神経系 (「CNS」)...
MASORI THERAPEUTICS AND VYANT BIO, INC. ANNOUNCE NEW PARTNERSHIP
19 oct. 2021 08h30 HE
|
Vyant Bio, Inc.
Engagement will combine MASORI’s global platforms and commercial experience in Japan to identify partnerships that leverage Vyant Bio’s advanced analytics and complex human-derived biology to drive...
MASORI THERAPEUTICS AND VYANT BIO, INC. ANNOUNCE NEW PARTNERSHIP
19 oct. 2021 08h30 HE
|
Vyant Bio, Inc.
Engagement will combine MASORI’s global platforms and commercial experience in Japan to identify partnerships that leverage Vyant Bio’s advanced analytics and complex human-derived biology to drive...
Vyant Bio to Present at the H.C. Wainwright 23rd Annual Global Conference
09 sept. 2021 08h00 HE
|
Vyant Bio, Inc.
Cherry Hill, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
19 août 2021 09h27 HE
|
Vyant Bio, Inc.
CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cureCollaboration creates opportunities to identify, validate, and...
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
16 août 2021 16h01 HE
|
Vyant Bio, Inc.
Strategic Highlights Received an issued US Patent titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States...